Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Mouse model tightly matches pediatric tumor syndrome, will speed drug hunt

Mouse model tightly matches pediatric tumor syndrome, will speed drug hunt

March 03, 2008

Frustrated by the slow pace of new drug development for a condition that causes pediatric brain tumors, a neurologist at Washington University School of Medicine in St. Louis decided to try to fine-tune the animal models used to test new drugs.

Instead of studying one mouse model of the disease causing the brain tumors, the laboratory of David Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology, evaluated three. They "auditioned" the three models to see which was the best match for neurofibromatosis 1, a genetic condition that increases the risk of brain tumors and afflicts more than 100,000 people in the United States.




Animal models have long been used to explore the basic physiology underlying disease and to tentatively try out new remedies, but Gutmann believes that creating a tighter match between the animal models and the human disorder will allow more extensive and more accurate preclinical testing of potential therapies.

"If you think of how we move drugs from testing in the laboratory to testing in humans, this is an exciting step that's likely to speed the translation from bench to bedside," says Gutmann, the senior author of a report in the March 1 Cancer Research. "With more extensive preclinical testing in the mice, we can make sure a new drug is reaching its target protein in tumor cells, we can learn whether the drug is killing tumor cells or shutting off their growth, and we can get some indication of whether the drug is likely to have an adverse effect on the developing brain."

Gutmann is director of the Washington University Neurofibromatosis Center, which facilitates multidisciplinary neurofibromatosis research and is dedicated to developing better treatments to improve the lives of patients affected by the disorder. Fifteen to 20 percent of children with neurofibromatosis 1 develop brain tumors called gliomas that arise from brain cells known as glial cells. Gutmann's lab has studied a mouse model of neurofibromatosis 1 for several years to gain a better understanding of how defects in the NF1 gene cause gliomas.

For the new study, Gutmann and colleagues Joshua Rubin, M.D., Ph.D., assistant professor of pediatrics, neurology and of neurobiology, and Joel Garbow, Ph.D., research associate professor of radiology, compared three mouse brain tumor models of neurofibromatosis 1. One of the models was the line his lab has previously used to study basic tumor biology.

To compare the mouse lines to the human disorder, researchers analyzed where the mice developed tumors, determined how quickly the tumor cells were dividing, and assessed when the tumors ceased growing. Based on these criteria, they learned that the model they had used earlier most faithfully reproduced the important features of the human condition. Researchers hope that this means the model will also give them the most accurate picture of how human patients are likely to respond to new treatments.

To test this theory, they gave the mice doses of a chemotherapy agent, temozolomide, currently in use clinically. Temozolomide slowed the growth and reduced the size of tumors in the mice, as it does in human patients.

Next researchers gave the mice rapamycin, an experimental drug currently in clinical trials as a treatment for other cancers. They found the drug was not killing tumor cells but preventing them from growing while the mice received regular doses of the drug. Higher doses could shut off tumor growth in a more long-lasting fashion, but also produced harmful side effects.

Because the trials were in mice, researchers could use a variety of invasive techniques to learn additional details about the effects of the drugs. For example, brain development is ongoing in young children, making the introduction of drugs that kill cells or stop their replication cause for significant concern. The mouse model let researchers look at developmental hotspots in the brain to see if temozolomide or rapamycin was adversely affecting the creation of new brain cells. They found that neither drug was.

Gutmann plans to use the mouse model in a new collaborative network funded by the Children's Tumor Foundation. His group and four other labs will test a variety of compounds against specific tumor types found in individuals affected with neurofibromatosis 1.

"We want to learn if these new drugs work the same in all aspects of the disease," Gutmann says. "We will be using what we learn to provide an efficient, rigorous pipeline for moving promising new drugs from the laboratory to clinical trials."

Washington University in St. Louis



Related Neurofibromatosis Current Events and Neurofibromatosis News Articles Neurofibromatosis Current Events and Neurofibromatosis News RSS Neurofibromatosis Current Events and Neurofibromatosis News RSS
Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers
Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.

New research strategy for understanding drug resistance in leukemia
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.

Anti-angiogenesis treatment improves hearing in some NF2 patients
Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2).

Chromosomal problems affect nearly all human embryos
For the first time, scientists have shown that chromosomal abnormalities are present in more than 90% of IVF embryos, even those produced by young, fertile couples.

Rice University study finds possible clues to epilepsy, autism
Rice University researchers have found a potential clue to the roots of epilepsy, autism, schizophrenia and other neurological disorders.

Mapping a clan of mobile selfish genes
Much of human DNA is the genetic equivalent of e-mail spam: short repeated sequences that have no obvious function other than making more of themselves.

Pediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma.

Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.

Gene's newly explained effect on height may change tumor disorder treatment
A mutation that causes a childhood tumor syndrome also impairs growth hormone secretion, researchers at Washington University School of Medicine in St. Louis have found.

Protein key to neuro-regeneration
Researchers at the Peninsula Medical School in the South West of England, University College London, the San Raffaele Scientific Institute in Milan and Cancer Research UK, have for the first time identified a protein that is key to the regeneration of damage in the peripheral nervous system and which could with further research lead to understanding diseases of our peripheral nervous systems and provide clues to methods of repairing damage in the central nervous system.
More Neurofibromatosis Current Events and Neurofibromatosis News Articles
Neurofibromatosis: A Handbook for Patients, Families and Health Care Professionals

Neurofibromatosis: A Handbook for Patients, Families and Health Care Professionals
by Bruce Korf (Editor), Allen Rubenstein (Editor)

Here is the state-of-the-art on recognizing, managing and living with neurofibromatosis (NF) for patients, families, and health care professionals. From new genetic and diagnostic advances, to associated cardiovascular and endocrine abnormalities, to the significant psychosocial impact of NF, the book is packed with clear, practical guidance for understanding and living with this disability.

Special features -

- A complete diagnostic guide to help you recognize NF-related symptoms--with a timeline for when they might appear

- New treatment options for NF, including pain control

- Coverage of the newly discovered form of NF, schwannomatosis

- Personal perspectives from NF patients and their families

- Glossary that defines medical terminology ...

Neurofibromatosis Medical Guide

Neurofibromatosis Medical Guide
by Qontro Medical Guides (Author)

The Neurofibromatosis Medical Guide is a publication which has been designed to better help readers understand Neurofibromatosis. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Neurofibromatosis. The Neurofibromatosis Medical Guide is highly recommended for those interested in understanding and learning more about Neurofibromatosis.

Neurofibromatosis: Phenotype, Natural History, and Pathogenesis (Johns Hopkins Series in Contemporary Medicine and Public Health)

Neurofibromatosis: Phenotype, Natural History, and Pathogenesis (Johns Hopkins Series in Contemporary Medicine and Public Health)
by Dr. J. M. Friedman MD PhD (Editor), Dr. David H. Gutmann MD-PhD (Editor), Dr. Mia MacCollin MD (Editor), Dr. Vincent M. Riccardi MD (Editor)

Univ. of British Columbia, Canada. Combines the Neurofibromatosis Institute Database with the International NF Database and the National NF Foundation. This edition sees an increased emphasis on NF2, in clinical and molecular terms. Previous edition: c1992. Includes evaluation and management, cognitive function and academic performance, and more.

  Neurofibromatosis: a young woman's journey--case study.(Case study): An article from: Journal of Neuroscience Nursing
by Susan Milliken (Author)

This digital document is an article from Journal of Neuroscience Nursing, published by Thomson Gale on December 1, 2007. The length of the article is 1833 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Neurofibromatosis: a young woman's journey--case study.(Case study)
Author: Susan Milliken
Publication: Journal of Neuroscience Nursing (Magazine/Journal)
Date: December 1, 2007
Publisher: Thomson Gale
Volume: 39 Issue: 6 Page: 332(4)

Article Type: Case study

Distributed by Thomson...

Neurofibromatosis Type I in Childhood

Neurofibromatosis Type I in Childhood
by Kathryn North (Author)

A great deal is now known about neurofibromatosis type 1, particularly as a result of the identification of its causative gene by positional cloning. However, effective treatments for its resulting cosmetic disfigurement, impaired cognitive performance and even life-threatening malignancy remain elusive. As Dr. Korf remarks in his Foreword: "this book's cogent and thorough description of neurofibromatosis in children will take its place alongside other major clinical studies of the disorder. [Dr. North] has tackled some of the more challenging issues, such as the basis for learning disabilities and the optimal means for early detection of optic gliomas. Her work provides a guide to the clinician and stands as a provocative challenge to the neurofibromatosis research community to further...

Living with Genetic Disorder: The Impact of Neurofibromatosis 1

Living with Genetic Disorder: The Impact of Neurofibromatosis 1
by Joan Ablon (Author)

A chronicle of the life experiences of adults with neurofibromatosis 1, a neurological genetic condition for many years misdiagnosed as "The Elephant Man's Disease." Affected persons deal with an unpredictable and potentially stigmatizing disorder, the symptoms of which range from physical disfigurement to severe learning disorders. Ablon offers suggestions for families, support systems, and health care providers to enhance coping skills and self image of the affected persons.

ABC News Nightline Listen Lesson in Patients

ABC News Nightline Listen Lesson in Patients

ABC News looks at how Harvard Medical School is creatively teaching its students one of the most important skills for a physician - how to listen to their patients. ABC News also meets Porter Colley, a 73- year old woman who suffers from neurofibromatosis.

Airdate: 9/1/2000

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.

Neurofibromatosis Awareness Ribbon Mouse Pad

Neurofibromatosis Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Neurofibromatosis Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Neurofibromatosis Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Neurofibromatosis Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

  Neurofibromatosis: Trusting God in the midst of NF
by Renee B Wilson (Author)



Neurofibromatosis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Neurofibromatosis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
by ICON Health Publications (Author)

In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so.

© 2009 BrightSurf.com